Alvotech (ALVO) to Release Quarterly Earnings on Wednesday

Alvotech (NASDAQ:ALVO) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 19th. Analysts expect Alvotech to announce earnings of ($0.0526) per share and revenue of $103.0040 million for the quarter. Individuals may review the information on the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:00 AM ET.

Alvotech Stock Performance

Shares of ALVO stock opened at $3.88 on Tuesday. Alvotech has a fifty-two week low of $2.94 and a fifty-two week high of $9.25. The stock has a 50 day simple moving average of $3.66 and a two-hundred day simple moving average of $3.77. The company has a market cap of $1.17 billion, a P/E ratio of -15.52 and a beta of 0.18.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings lowered shares of Alvotech from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. Evercore started coverage on shares of Alvotech in a research note on Friday. They set an “outperform” rating on the stock. Finally, Wall Street Zen cut shares of Alvotech from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.60.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Jane Street Group LLC purchased a new stake in Alvotech in the 4th quarter valued at $474,000. Goldman Sachs Group Inc. lifted its stake in Alvotech by 88.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 259,536 shares of the company’s stock valued at $1,331,000 after acquiring an additional 122,089 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Alvotech by 10.7% during the 4th quarter. Geode Capital Management LLC now owns 254,921 shares of the company’s stock worth $1,308,000 after acquiring an additional 24,667 shares during the last quarter. Citadel Advisors LLC purchased a new position in Alvotech during the 3rd quarter worth $346,000. Finally, Gilder Gagnon Howe & Co. LLC purchased a new position in Alvotech during the 2nd quarter worth $1,782,000.

About Alvotech

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).